CRBP

$8.24-22.23%

Corbus Pharmaceuticals Holdings, Inc.

Market Cap

$205M

Sector

Materials

Industry

Biotechnology

Beta

2.71

5yr monthly vs SPY

Price Chart

Loading…

Signals

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →

Buy Activity

Buy Velocity Score

24.85x

Current Rate (90d)

178.89/mo

Baseline Rate

0.00/mo

Unique Buyers (90d)

Sell Activity

Sell Velocity Score

11.05x

Sell Rate (90d)

424.87/mo

Sell Baseline

104.15/mo

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-08-11	2026-08-12	Saxena Nishant C	Chief Business Officer	Purchase	2,600	$9.63	$25K	77.9K	View
2026-08-07	2026-08-10	Moran Sean F.	Chief Financial Officer	Sale	12.0K	$10.08	$121K	84.7K	View
2026-08-07	2026-08-10	Cohen Yuval	Director & Chief Executive Officer	Sale	17.0K	$10.08	$171K	157.3K	View
2026-06-10	2026-06-11	Kung Winston	Director	Sale	2,026	$7.91	$16K	12.1K	View
2026-06-10	2026-06-11	Jenkins John Kenneth	Director	Sale	4,800	$7.91	$38K	3,833	View

1–5 of 12

1 / 3

Recent News

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

Yahoo Finance · 2026-08-06

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Yahoo Finance · 2026-08-04

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Yahoo Finance · 2026-07-28

Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

Informational purposes only, not investment advice.